Medicine and Dentistry
Malignant Neoplasm
80%
Overall Survival
62%
Diseases
61%
Breast Cancer
51%
Castration Resistant Prostate Cancer
50%
Clinical Trial
48%
Prostate Cancer
47%
Progression Free Survival
44%
Metastatic Carcinoma
44%
BRCA1
44%
Kidney Metastasis
43%
Sunitinib
42%
Pembrolizumab
42%
Biological Marker
38%
Neoplasm
38%
Recurrent Disease
32%
Adverse Event
31%
Radiation Therapy
31%
Ovarian Cancer
30%
Oncology
29%
Transitional Cell Carcinoma
29%
Immunotherapy
28%
Transcriptomics
27%
Biochemical Recurrence
26%
Targeted Therapy
26%
Cancer Therapy
25%
Hazard Ratio
22%
Clear Cell Renal Cell Carcinoma
21%
Solid Malignant Neoplasm
20%
Personalized Medicine
20%
BRCA2
20%
Computer Assisted Tomography
19%
Prostate Specific Antigen
18%
Antineoplastic Activity
18%
Cancer Risk
18%
Prostate Specific Membrane Antigen
17%
Medicine
17%
Arm
16%
Lymphocyte
15%
Pancreas Adenocarcinoma
14%
Ascites
14%
Urothelial Cancer
14%
Pancreas Cancer
14%
Niraparib
14%
Antibody Response
14%
Hypofractionated Radiotherapy
14%
Abiraterone Acetate
14%
Cabozantinib
14%
Polyethylene Terephthalate
14%
Androgen Deprivation Therapy
13%
Keyphrases
Sunitinib
57%
Metastatic Renal Cell Carcinoma (mRCC)
56%
Overall Survival
56%
Chemotherapy
54%
Breast Cancer Susceptibility Gene 1 (BRCA1)
53%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
52%
Pembrolizumab
50%
Progression-free Survival
46%
Prostate-specific Antigen
39%
Clinical Trials
38%
Breast Cancer
37%
BRCA2 mutation
33%
Tumor
31%
Response Rate
31%
BRCA mutation Carriers
31%
Phase II Trial
30%
BRCA2
29%
Programmed Death-ligand 1 (PD-L1)
28%
Hazard Ratio
27%
Biochemical Failure
26%
Breast Cancer Risk
25%
Pancreatic Ductal Adenocarcinoma
25%
Ovarian Cancer
23%
Prostate
23%
Antitumor Activity
23%
Ovarian Cancer Risk
22%
Thymopoietin
21%
Pancreatic Cancer
21%
LCS101
21%
Abiraterone Acetate
21%
Metastatic Disease
20%
Anticancer Effect
20%
Radiation Therapy
20%
Cancer Cells
20%
Complete Response
19%
In Cancer
19%
Confidence Interval
18%
Patients with Cancer
17%
Personalized Medicine
17%
Patient Response
17%
Israeli
17%
Precision Oncology
17%
Personalized Cancer Therapy
17%
Cancer Patients
17%
Prostate Cancer Patients
17%
BRCA1, BRCA2
17%
Docetaxel
17%
Adverse Events
17%
Overall Survival of Patients
17%
Partial Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Diseases
66%
Overall Survival
63%
Chemotherapy
57%
Castration Resistant Prostate Cancer
57%
Sunitinib
57%
Progression Free Survival
55%
Breast Cancer
52%
Neoplasm
52%
Pembrolizumab
50%
Kidney Metastasis
36%
Prostate Cancer
36%
Adverse Event
31%
Renal Cell Carcinoma
28%
Clinical Trial
28%
Transitional Cell Carcinoma
27%
Prostate Specific Membrane Antigen
25%
Biological Marker
24%
Abiraterone Acetate
21%
Solid Malignant Neoplasm
21%
Docetaxel
17%
Antitumor Activity
17%
Prostate Specific Antigen
16%
Colorectal Carcinoma
16%
Triple Negative Breast Cancer
15%
Metastatic Colorectal Cancer
14%
Cabozantinib
14%
Somatomedin C Receptor
14%
Radioisotope
14%
Membrane Antigen
14%
Lutetium 177
14%
Receptor
13%
Recurrent Disease
13%
Retrospective Study
12%
Side Effect
11%
Disease Exacerbation
11%
Doxorubicin
10%
Biochemical Recurrence
10%
Immune Checkpoint Inhibitor
10%
Programmed Death 1 Ligand 1
9%
Immunotherapy
9%
microRNA
9%
Fluorouracil
9%
Reactive Oxygen Metabolite
9%
Colon Carcinoma
9%
Insulin-Like Growth Factor 1
9%
Non Small Cell Lung Cancer
8%
Cancer Model
8%
Pharmacokinetics
8%
Liver Metastasis
8%